Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Publication|Articles|June 18, 2025
- June 2025
- Volume 31
- Issue Spec. No. 7
- Pages: SP402-SP404
Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?
Author(s)Mary Caffrey
Advertisement
Advertisement
By this fall, the FDA may approve a subcutaneous (SC) injection of the world’s top-selling cancer drug, pembrolizumab (Keytruda; Merck), that can be delivered to patients in 5 minutes or less. It is a change that Merck’s Marjorie Green, MD, senior vice president and head of oncology clinical development, predicts will “build on this breakthrough medicine to give patients and those who treat them better experiences.”1
Related to this article
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Advertisement
Advertisement